198 related articles for article (PubMed ID: 23993342)
41. Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery.
Gao H; Zhang S; Cao S; Yang Z; Pang Z; Jiang X
Mol Pharm; 2014 Aug; 11(8):2755-63. PubMed ID: 24983928
[TBL] [Abstract][Full Text] [Related]
42. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
[TBL] [Abstract][Full Text] [Related]
43. Peptide-based glioma-targeted drug delivery vector gHoPe2.
Eriste E; Kurrikoff K; Suhorutšenko J; Oskolkov N; Copolovici DM; Jones S; Laakkonen P; Howl J; Langel Ü
Bioconjug Chem; 2013 Mar; 24(3):305-13. PubMed ID: 23350661
[TBL] [Abstract][Full Text] [Related]
44. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
45. EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
Zhang B; Wang H; Liao Z; Wang Y; Hu Y; Yang J; Shen S; Chen J; Mei H; Shi W; Hu Y; Pang Z; Jiang X
Biomaterials; 2014 Apr; 35(13):4133-45. PubMed ID: 24529623
[TBL] [Abstract][Full Text] [Related]
46. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
47. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
48. Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma.
Zhang L; Zhang Y; Tai L; Jiang K; Xie C; Li Z; Lin YZ; Wei G; Lu W; Pan W
Acta Biomater; 2016 Sep; 42():90-101. PubMed ID: 27370905
[TBL] [Abstract][Full Text] [Related]
49. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals.
Qin Y; Chen H; Zhang Q; Wang X; Yuan W; Kuai R; Tang J; Zhang L; Zhang Z; Zhang Q; Liu J; He Q
Int J Pharm; 2011 Nov; 420(2):304-12. PubMed ID: 21945185
[TBL] [Abstract][Full Text] [Related]
50. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.
Lu RM; Chang YL; Chen MS; Wu HC
Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768
[TBL] [Abstract][Full Text] [Related]
51. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles.
Gao H; Qian J; Cao S; Yang Z; Pang Z; Pan S; Fan L; Xi Z; Jiang X; Zhang Q
Biomaterials; 2012 Jul; 33(20):5115-23. PubMed ID: 22484043
[TBL] [Abstract][Full Text] [Related]
52. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.
Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY
ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677
[TBL] [Abstract][Full Text] [Related]
53. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
54. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.
Yang ZZ; Li JQ; Wang ZZ; Dong DW; Qi XR
Biomaterials; 2014 Jun; 35(19):5226-39. PubMed ID: 24695093
[TBL] [Abstract][Full Text] [Related]
55. Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.
Kuang Y; Jiang X; Zhang Y; Lu Y; Ma H; Guo Y; Zhang Y; An S; Li J; Liu L; Wu Y; Liang J; Jiang C
Mol Pharm; 2016 May; 13(5):1599-607. PubMed ID: 27058780
[TBL] [Abstract][Full Text] [Related]
56. Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.
Chen C; Duan Z; Yuan Y; Li R; Pang L; Liang J; Xu X; Wang J
ACS Appl Mater Interfaces; 2017 Feb; 9(7):5864-5873. PubMed ID: 28128553
[TBL] [Abstract][Full Text] [Related]
57. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles.
Xin H; Sha X; Jiang X; Zhang W; Chen L; Fang X
Biomaterials; 2012 Nov; 33(32):8167-76. PubMed ID: 22889488
[TBL] [Abstract][Full Text] [Related]
58. Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin.
Zhao Y; Yin H; Zhang X
Aging (Albany NY); 2020 May; 12(11):10506-10516. PubMed ID: 32474457
[TBL] [Abstract][Full Text] [Related]
59. In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL.
Fan H; Hu QD; Xu FJ; Liang WQ; Tang GP; Yang WT
Biomaterials; 2012 Feb; 33(5):1428-36. PubMed ID: 22079004
[TBL] [Abstract][Full Text] [Related]
60. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
